| Objective:Through clinical research of using the Ajuga decoction to treat primary mesangial proliferative glomerulonephritis (MsPGN), observe the impact of the clinical and laboratory indicators of Ajuga decoction treatment of MsPGN, and explore the effectiveness, security and mechanism of action, in order to provide a scientific basis for clinical research and application.Methods:All60cases were collected from Nephrology and Traditional Chinese Medicine department of Fuzhou General Hospital of the Nanjing Military Region from January2011to January2012, those confirmed the mesangial roliferative glomerulonephritis and met the inclusion criteria contained the24-hour urinary protein between1～3g,etc. The patients were divided into control group (30cases)and Ajuga treatment group (30cases) randomly. Both groups were given the low-salt and high-quality protein diet [0.8-1.Og/(kg.d)] etc. The control group given benazepril (Lotensin)1Omg twice a day and dipyridamole25mg three times a day by oral, at the same time the Ajuga treatment group was added Ajuga decoction on the basis of the control group,a dose of20g one day, warm-taken three times a day. Both two groups were treated for6weeks. At before treatment and treatment of2,6weeks, we test the points in the24-hour urine protein quantification, urine red blood cell count, plasma albumin (ALB), serum total cholesterol(TC), serum creatinine(Scr) and urinary albumin/creatinine ratio (ACR),urinary interleukin-6(IL-6)and safety indicators respectively.Results:1. Proteinuria:24h urine protein of Ajuga treatment group significantly reduced after treatment [(1.77±0.51)mg/24h vs(0.64±0.34)mg/24h, P<0.05], the effective than the control group [(0.64±0.34)mg/24h vs (0.88±0.45)mg/24h, P<0.05], and relieve urinary protein total efficiency90.0%higher than that82.7%in the control group, with statistical significance (P<0.05). The two groups of urinary albumin/creatinine ratio both decreased, with significant differences between groups [(51.26±33.76)mg/mmol vs(71.46±42.59)mg/mmol, P<0.05].2. Urinary red blood cell count:Ajuga treatment group can reduce urinary red blood cell count [(116.23±69.16)/ul vs(48.07±29.08)/ul, P<0.05], superior to the control group, there was significant differences [(48.07±29.08)/ul vs (80.70±63.02)/ul, P<0.05].3.biochemical indicators: Throughout the course of treatment, both ALB levels of two groups showed a rising trend compare with that before treatment, TC of the treatment group showed a downward trend, but there were no significant difference between the two groups and within the group(P>0.05).there were no significant changes in the level of Scr before and after treatment too(P>0.05).4. Urinary interleukin-6:the Ajuga treatment group can effectively reduce the urine of patients with IL-6level[(257.70±47.98)pg/ml vs(146.98±42.77)pg/ml, P<0.05], superior to treatment group,with significant differences [(146.98±42.77) pg/ml vs (172.60±45.62)pg/ml,P<0.05].5. The observed side effects:A total of three cases of patients appeared dry cough, two cases in which treatment group and1cases ontrol group1cases, consider taking Lotensin related. one patient of the treatment group was found the stool changing after taking the the Ajuga decoction five days. Found no abnormal in blood count, liver function, electrolytes, and other safety indicators related to the taking of Ajuga soup.Conclusions:1.Ajuga decoction can effectively reduce urinary protein levels and the urinary red blood cell count of the MsPGN patients; by reducing urinary level of IL-6, it may relieve the local inflammatory reaction and play the role of treating disease and protecting the kidney.2It is safe and effective for clinical application of the Ajuga treatment of MsPGN, without significant liver and kidney toxicity,worthy of further clinical research. |
PDF Full Text Request